Nyrada Inc
NYR
Company Profile
Business description
Nyrada Inc is a preclinical-stage, drug discovery, and development company, specializing in novel small-molecule drugs to treat cardiovascular and neurological diseases. The company's two programs center on cholesterol-lowering and brain injury, each targeting market sectors of notable size and unmet clinical needs. The programs are focused on developing an oral, small molecule cholesterol-lowering drug, and a drug to treat secondary brain damage following a stroke or traumatic brain injury.
Contact
828 Pacific Highway
Suite 2, Level 3
GordonNSW2072
AUST: +61 294983390
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
Stocks News & Analysis
stocks
Perplexing buyback from overvalued ASX share
Earnings continue to grow but investor expectations are too high.
stocks
Most popular shares in SMSFs
With data showing the continued rise of SMSFs, we explore the top stock picks of individual investors
stocks
Will China strong arm BHP into lower iron ore prices?
Allegations that the Chinese government told steel mills to stop buying from BHP shake markets.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,208.50 | 9.00 | -0.10% |
| CAC 40 | 7,851.76 | 82.50 | -1.04% |
| DAX 40 | 24,076.20 | 311.73 | -1.28% |
| Dow JONES (US) | 46,067.58 | 587.98 | 1.29% |
| FTSE 100 | 9,403.26 | 39.61 | -0.42% |
| HKSE | 25,441.35 | 448.13 | -1.73% |
| NASDAQ | 22,694.61 | 490.18 | 2.21% |
| Nikkei 225 | 46,847.32 | 1,241.48 | -2.58% |
| NZX 50 Index | 13,276.99 | 74.93 | -0.56% |
| S&P 500 | 6,654.72 | 102.21 | 1.56% |
| S&P/ASX 200 | 8,899.40 | 10.30 | -0.12% |
| SSE Composite Index | 3,865.23 | 24.27 | -0.62% |